Navigation Links
ATL/TV1102 Trial Results Presented at World Congress on Treatment and Research in Multiple Sclerosis
Date:9/21/2008

eva Pharmaceutical Industries Ltd.

About Isis Pharmaceuticals, Inc.

Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world's first antisense drug and has 19 drugs in development. Isis' drug development programs are focused on treating cardiovascular and metabolic diseases. Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases. Ibis Biosciences, Inc., Isis' majority-owned subsidiary, is developing and commercializing the Ibis T5000(TM) Biosensor System, a revolutionary system to identify infectious organisms. Isis is a joint owner of Regulus Therapeutics LLC, a joint venture focused on the discovery, development and commercialization of microRNA therapeutics. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,500 issued patents worldwide. Additional information about Isis is available at http://www.isispharm.com.

Isis Forward-Looking Statement

This press release includes forward-looking statements regarding Isis' business, its drug discovery and development pipeline, and the therapeutic potential of ATL/TV1102 for the treatment of multiple sclerosis. Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement, including those statements that are described as Isis' goals. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such products. Isis' forward-looking statements also involve assumptions that, if they never materialize or pro
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.; Antisense Therapeutics Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 ... research report is available in its ... Markets and Technologies for Advanced Drug ... of Administration ...
(Date:1/14/2014)... 2014 HeartWare International, Inc . (NASDAQ: ... miniaturized circulatory support technologies that are revolutionizing the treatment ... revenues for the fourth quarter of 2013 will be ... approximately $208 million. "Our full-year revenue growth ...
(Date:1/14/2014)... HILLS, Calif. , Jan. 14, 2014 The Brandeis Medical ... Los Angeles a premier and affordable laser tattoo removal ... special. Dr. Brandeis, focus is in providing high quality cosmetic services ... all patients. " Southern California has ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2
... , , , , SAN DIEGO and TOKYO, Dec. ... announced that they have entered into a worldwide agreement to ... non-oncology indications. This partnership includes AC220, Ambit,s lead clinical-stage ... earlier this month in relapsed/refractory acute myeloid leukemia (AML), and ...
... Amnis Corporation, a manufacturer of advanced cell imaging systems, ... Annual J.P. Morgan Healthcare Conference. The Conference will be held ... Francisco. David Basiji, Ph.D., Amnis, President and Chief Executive ... in Room F and will discuss the company,s novel technology, ...
Cached Medicine Technology:Ambit Biosciences and Astellas Enter Strategic Partnership to Research, Develop and Commercialize FLT3 Kinase Inhibitors in Multiple Indications 2Ambit Biosciences and Astellas Enter Strategic Partnership to Research, Develop and Commercialize FLT3 Kinase Inhibitors in Multiple Indications 3Ambit Biosciences and Astellas Enter Strategic Partnership to Research, Develop and Commercialize FLT3 Kinase Inhibitors in Multiple Indications 4Ambit Biosciences and Astellas Enter Strategic Partnership to Research, Develop and Commercialize FLT3 Kinase Inhibitors in Multiple Indications 5
(Date:7/10/2014)... felt better prepared to respond to an active shooter ... new study in the journal Prehospital and Disaster ... examine the EMS provider comfort level with respect to ... been neutralized or working with law enforcement personnel during ... School shooting, the Virginia Tech campus shooting, the 2009 ...
(Date:7/10/2014)... as the "Mississippi baby" an infant seemingly cured of ... prolonged remission of HIV infection in The New England ... HIV after more than two years of not taking antiretroviral ... specialist and researchers involved in the case. , ... young child, the medical staff involved in the child,s care, ...
(Date:7/10/2014)... Estonian-born Katerina Alba,s research at the University of Huddersfield ... the most popular emulsion-based food products such as ... is starting to gain an international profile for her ... and food science at the University and now she ... with her supervisor, Dr Vassilis Kontogiorgos, she is investigating ...
(Date:7/10/2014)... were more likely to be diagnosed with more ... survived for shorter times than prostate cancer patients ... found. , The negative outcomes may be the ... the mentally ill, depression,s impact on biological cancer ... his general health and disinterest in receiving more ...
(Date:7/9/2014)... WASHINGTON, DC (July 10, 2014) If you think winning ... fun for kids think again: Winning along with other mental ... each of which falls into one of 11 big fun ... that winning is all important when it comes to the ... identify and quantify what goes into this elusive conceptuntil now. ...
Breaking Medicine News(10 mins):Health News:Active shooter training increases comfort level of emergency responders 2Health News:'Mississippi Baby' now has detectable HIV, researchers find 2Health News:'Mississippi Baby' now has detectable HIV, researchers find 3Health News:World interest in research work on the benefits of the Okra plant 2Health News:Depressed men with prostate cancer are diagnosed later stage, get less effective therapies 2Health News:Being a good sport ranks as the top 'fun' factor in study of youth sports 2Health News:Being a good sport ranks as the top 'fun' factor in study of youth sports 3
... Crazy While They Work...30,000+ Dentists Converge in Chicago February ... issued by the Chicago Dental Society:Who: The Chicago ... to find out some wacky, unusual, and just plain ... chair.As we countdown to CDS,s annual Midwinter Meeting, one ...
... to new dental techniques, , , TUESDAY, Feb. 24 (HealthDay ... immune function and the development of skin and the ... Oregon State University researchers have found. , Their discovery ... to new methods of repairing damaged enamel and preventing ...
... music doesn,t necessary cause promiscuity, experts stress, , , ... proof that raunchy music makes kids have sex, but a ... kind of link between "degrading" songs and teenage sexual activity. ... to certain messages in music are more likely to copy ...
... uses search engine optimization and individualized marketing to offer ... 24 Creative Marketing Solutions, LLC (CMS) today announced ... cost-effective way for veterinary practices to market themselves online, ... Much more than just a listing service, My Hometown ...
... Make Them Effective , ... St. Louis, MO (PRWEB) February 24, 2009 ... or some would say failing - health care system at further risk. ... rising. Also, faced with tighter budgets and escalating health care costs, even ...
... 24 With President Obama preparing to,present his budget ... on,his economic stimulus initiatives and a renewed call for ... released new data,on how the most comprehensive healthcare fix ... national economy. , Overall, expanding ...
Cached Medicine News:Health News:Top 5 Most Annoying Dental Patient Behaviors 2Health News:Scientists Find Gene for Tooth Enamel 2Health News:'Degrading' Lyrics Linked to Teen Sex 2Health News:'Degrading' Lyrics Linked to Teen Sex 3Health News:Creative Marketing Solutions Launches My Hometown Vet, Giving Veterinary Practices Better Visibility Online 2Health News:Creative Marketing Solutions Launches My Hometown Vet, Giving Veterinary Practices Better Visibility Online 3Health News:Health and Wellness Programs in a Tight Economy 2
1% tryptone, 0.5% yeast extract, 1.0% Sodium Chloride. 1.5% agararose...
Luria bertani broth: 1.0% Tryptone, 0.5% Yeast Extract, 1.0% Sodium Chloride....
... flowing powder. pH: pH(4.7%, H 2 O): ... Yeast Extract: 47% Potassium Phosphate Dibasic: 25% Potassium ... 47 gm powder per liter of purified water. ... and recombinant proteins than LB media by allowing ...
1.2% Tryptone, 2.4% Yeast Extract, 0.4% Glycerol, with 100ml of 10x Phosphate buffer supplement (0190-01)....
Medicine Products: